MYGN

Myriad Genetics, Inc.
CAPPED RATING

Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.

Myriad Genetics, Inc. (MYGN) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Revisions (F). The rating has held at C for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
B
Factor Score 3.3 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -9.5
EV / EBITDA -11.4
Rev Growth YoY -1.5%
Gross Margin 68.3%
Price Return 3M 87.5%
Price Return 12M -15.0%
Catalyst Signal 0.00
Market Cap $544.8M
TTM Revenue $803.6M
Price / Sales 0.7
ROE -40.2%

Historical Factor Score Progression

Held C for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) C- (2.0) B- (3.0) B (3.3) F (0.0) C (2.3)
2026-11-06 B- (3.0) C- (2.1) B- (3.0) B (3.2) F (0.0) C (2.3)
2026-10-30 B- (3.0) C- (2.0) B- (3.0) B- (2.9) F (0.0) C (2.2)
2026-10-23 B- (3.0) C- (2.0) B- (3.0) C (2.2) F (0.0) C- (2.1)
2026-10-16 B- (3.0) C- (2.0) B- (3.0) D+ (1.6) F (0.0) C- (1.9)
Page 1 of 3